Clinical characteristics and treatment of the 29 ML-DS patients at initial diagnosis
| . | No. . | % . |
|---|---|---|
| Age, y | ||
| Median (range) | 2 (0.6-16) | |
| 0- < 1 | 2 | 6.9 |
| 1 ≤ - < 2 | 9 | 31.0 |
| 2 ≤ - < 3 | 6 | 20.7 |
| 3 ≤ - < 4 | 6 | 20.7 |
| 4 ≤ | 6 | 20.7 |
| Sex | ||
| Male | 18 | 62.1 |
| Female | 11 | 37.9 |
| WBC, × 109/L | ||
| Median (range) | 5.6 (0.9-143.6) | |
| FAB classification | ||
| M1 | 1 | 3.5 |
| M2 | 1 | 3.5 |
| M5 | 1 | 3.5 |
| M7 | 22 | 75.8 |
| MDS/unclassified | 4 | 13.7 |
| Karyotype | ||
| Constitutional trisomy 21 | 6 | 20.7 |
| Monosomy 7 | 2 | 6.9 |
| −7+ring/marker | 5 | 17.2 |
| t(8;21)(q22;q22) | 1 | 3.5 |
| Other abnormalities | 13 | 44.8 |
| Not available | 2 | 6.9 |
| Initial treatment for ML-DS | ||
| AML99 Down protocol | 20 | 69.0 |
| JCCLSG AML9805 Down protocol | 1 | 3.5 |
| JPLSG AML-D05 | 8 | 27.5 |
| . | No. . | % . |
|---|---|---|
| Age, y | ||
| Median (range) | 2 (0.6-16) | |
| 0- < 1 | 2 | 6.9 |
| 1 ≤ - < 2 | 9 | 31.0 |
| 2 ≤ - < 3 | 6 | 20.7 |
| 3 ≤ - < 4 | 6 | 20.7 |
| 4 ≤ | 6 | 20.7 |
| Sex | ||
| Male | 18 | 62.1 |
| Female | 11 | 37.9 |
| WBC, × 109/L | ||
| Median (range) | 5.6 (0.9-143.6) | |
| FAB classification | ||
| M1 | 1 | 3.5 |
| M2 | 1 | 3.5 |
| M5 | 1 | 3.5 |
| M7 | 22 | 75.8 |
| MDS/unclassified | 4 | 13.7 |
| Karyotype | ||
| Constitutional trisomy 21 | 6 | 20.7 |
| Monosomy 7 | 2 | 6.9 |
| −7+ring/marker | 5 | 17.2 |
| t(8;21)(q22;q22) | 1 | 3.5 |
| Other abnormalities | 13 | 44.8 |
| Not available | 2 | 6.9 |
| Initial treatment for ML-DS | ||
| AML99 Down protocol | 20 | 69.0 |
| JCCLSG AML9805 Down protocol | 1 | 3.5 |
| JPLSG AML-D05 | 8 | 27.5 |
FAB indicates French-American-British; JCCLSG, Japanese Children's Cancer and Leukemia Study Group; JPLSG, Japanese Pediatric Leukemia/Lymphoma Study Group; MDS, myelodysplastic syndrome; ML-DS, myeloid leukemia in Down syndrome; and WBC, white blood cell count.